As of 2025-12-25, the EV/EBITDA ratio of Cardiff Oncology Inc (CRDF) is -3.83. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Cardiff's latest enterprise value is 204.07 mil USD. Cardiff's TTM EBITDA according to its financial statements is -53.33 mil USD. Dividing these 2 quantities gives us the above Cardiff EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.3x - 15.5x | 15.3x |
| Forward P/E multiples | 19.8x - 35.7x | 22.2x |
| Fair Price | (15.49) - (12.09) | (14.69) |
| Upside | -587.2% - -480.1% | -562.0% |
| Date | EV/EBITDA |
| 2025-12-22 | -3.50 |
| 2025-12-19 | -3.06 |
| 2025-12-18 | -2.97 |
| 2025-12-17 | -2.85 |
| 2025-12-16 | -2.84 |
| 2025-12-15 | -2.85 |
| 2025-12-12 | -2.83 |
| 2025-12-11 | -2.94 |
| 2025-12-10 | -2.90 |
| 2025-12-09 | -2.85 |
| 2025-12-08 | -2.77 |
| 2025-12-05 | -2.48 |
| 2025-12-04 | -2.54 |
| 2025-12-03 | -2.50 |
| 2025-12-02 | -2.39 |
| 2025-12-01 | -2.55 |
| 2025-11-28 | -2.69 |
| 2025-11-26 | -2.77 |
| 2025-11-25 | -2.48 |
| 2025-11-24 | -2.44 |
| 2025-11-21 | -2.37 |
| 2025-11-20 | -2.29 |
| 2025-11-19 | -2.34 |
| 2025-11-18 | -2.39 |
| 2025-11-17 | -2.41 |
| 2025-11-14 | -2.50 |
| 2025-11-13 | -2.53 |
| 2025-11-12 | -2.64 |
| 2025-11-11 | -2.70 |
| 2025-11-10 | -2.63 |
| 2025-11-07 | -2.58 |
| 2025-11-06 | -2.65 |
| 2025-11-05 | -2.64 |
| 2025-11-04 | -2.61 |
| 2025-11-03 | -2.73 |
| 2025-10-31 | -2.78 |
| 2025-10-30 | -2.63 |
| 2025-10-29 | -2.64 |
| 2025-10-28 | -2.72 |
| 2025-10-27 | -2.70 |
| 2025-10-24 | -2.63 |
| 2025-10-23 | -2.60 |
| 2025-10-22 | -2.54 |
| 2025-10-21 | -2.63 |
| 2025-10-20 | -2.69 |
| 2025-10-17 | -2.58 |
| 2025-10-16 | -2.64 |
| 2025-10-15 | -2.85 |
| 2025-10-14 | -2.68 |
| 2025-10-13 | -2.66 |